mainly found in lung cancer, breast cancer, pancreatic cancer, and others. The NRG1 gene fusion leads to abnormal activation of signaling pathways through the ERBB family (especially ERBB3 and ERBB2/HER2), which promotes the growth and differentiation of cancer cells. Therefore, targeted therapies...
参考来源: FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. FDA. December 4, 2024. Accessed December 4, 2024. Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in ...
参考来源: FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. FDA. December 4, 2024. Accessed December 4, 2024. Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in ...
This review focuses on the biology and detection ofNRG1fusions and the evolving therapeutic landscape of NSCLC harboringNRG1fusions.#Zenocutuzumab, a bispecific antibody targeting HER2 and HER3, is the first FDA approved treatment for previously treatedNRG1fusion-positive NSCLC and pancreatic cancer....
“This medicine fills an important need among patients withNRG1fusionpancreatic adenocarcinoma and lung cancer who have not previously had targeted treatment options,” said Alison Schram M.D., an attending medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Cente...
Merus N.V. (Nasdaq: MRUS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or m...
[1]FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer.https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-zenocutuzumab-for-nrg1-pancreatic-cancer [2]Zenocutuzumab (Zeno) granted breakthrough therapy designation by the US Food & Dru...
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01005-1 Download citation Published20 February 2025 DOIhttps://doi.org/10.1038/s41571-025-01005-1 Subjects Lung cancer Pancreatic cancer Targeted therapies ...
Responses were observed in multiple tumor types — including in 27 of 93 patients (29%; 95% CI, 20 to 39) with non–small-cell lung cancer (NSCLC) and 15 of 36 patients (42%; 95% CI, 25 to 59) with pancreatic cancer — and across multiple NRG1 fusion par... 收藏 分享 下载 ...
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene Genes Chromosom Cancer, 37 (2003), pp. 333-345 View in ScopusGoogle Scholar 24. Y. Wang, X. Ding, S. Wang, et al. Antitumor effect of FGFR inhibitors on a novel ch...